Cargando…

What’s beyond BRCA Mutational Status in High Grade Serous Ovarian Cancer? The Impact of Hormone Receptor Expression in a Large BRCA-Profiled Ovarian Cancer Patient Series: A Retrospective Cohort Study

SIMPLE SUMMARY: Ovarian hormones are involved in ovarian cancer pathogenesis. However, few reports have investigated the hormone receptor pattern according to BRCA mutational status. The aim of this single-center, observational, retrospective study was to explore the relationship between hormone rec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perrone, Emanuele, Tudisco, Riccardo, Pafundi, Pia Clara, Guido, Davide, Ciucci, Alessandra, Martinelli, Enrica, Zannoni, Gian Franco, Piermattei, Alessia, Spadola, Saveria, Ferrante, Giulia, Marchetti, Claudia, Scambia, Giovanni, Fagotti, Anna, Gallo, Daniela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559459/ https://www.ncbi.nlm.nih.gov/pubmed/36230510 http://dx.doi.org/10.3390/cancers14194588

Ejemplares similares

Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients
por: Buttarelli, Marianna, et al.
Publicado: (2022)

Pathological Chemotherapy Response Score in Patients Affected by High Grade Serous Ovarian Carcinoma: The Prognostic Role of Omental and Ovarian Residual Disease
por: Santoro, Angela, et al.
Publicado: (2019)

NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer
por: Marchetti, Claudia, et al.
Publicado: (2021)

Multiple direct and indirect mechanisms drive estrogen-induced tumor growth in high grade serous ovarian cancers
por: Ciucci, Alessandra, et al.
Publicado: (2016)

Ovarian low and high grade serous carcinomas: hidden divergent features in the tumor microenvironment
por: Ciucci, Alessandra, et al.
Publicado: (2016)

Deep-Learning to Predict BRCA Mutation and Survival from Digital H&E Slides of Epithelial Ovarian Cancer
por: Nero, Camilla, et al.
Publicado: (2022)

Clinical Value of lncRNA MEG3 in High-Grade Serous Ovarian Cancer
por: Buttarelli, Marianna, et al.
Publicado: (2020)

Exploring the Control of PARP1 Levels in High-Grade Serous Ovarian Cancer
por: Raspaglio, Giuseppina, et al.
Publicado: (2023)

BRCA and Early Events in the Development of Serous Ovarian Cancer
por: George, Sophia H. L., et al.
Publicado: (2014)

Tumor BRCA testing in ovarian cancer and EQA scheme: our experience of a critical evaluation
por: De Paolis, Elisa, et al.
Publicado: (2021)

Expression of the Glioma-Associated Oncogene Homolog 1 (Gli1) in Advanced Serous Ovarian Cancer Is Associated with Unfavorable Overall Survival
por: Ciucci, Alessandra, et al.
Publicado: (2013)

Preclinical models of epithelial ovarian cancer: practical considerations and challenges for a meaningful application
por: Ciucci, Alessandra, et al.
Publicado: (2022)

Characterization of BRCA Deficiency in Ovarian Cancer
por: Barbero, Giovanna, et al.
Publicado: (2023)

The prognostic role of systemic inflammatory markers in apparent early-stage ovarian cancer
por: Bizzarri, Nicolò, et al.
Publicado: (2022)

In search for biomarkers and potential drug targets for uterine serous endometrial cancer
por: Dinoi, Giorgia, et al.
Publicado: (2021)

Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer
por: Lee, Chee Khoon, et al.
Publicado: (2019)

BRCA immunohistochemistry for screening of BRCA mutation in epithelial ovarian cancer patients
por: Manchana, Tarinee, et al.
Publicado: (2020)

The BRCA Gene in Epithelial Ovarian Cancer
por: Sánchez-Lorenzo, Luisa, et al.
Publicado: (2022)

Preoperative Anti-Class III β-Tubulin Antibodies As Relevant Clinical Biomarkers in Ovarian Cancer
por: Martinelli, Enrica, et al.
Publicado: (2018)

Transcriptome Patterns of BRCA1- and BRCA2- Mutated Breast and Ovarian Cancers
por: Arakelyan, Arsen, et al.
Publicado: (2021)

Hypoxia-Activated Alkylating Agents in BRCA1-Mutant Ovarian Serous Carcinoma
por: Conroy, Michael, et al.
Publicado: (2017)

CD133 antigen expression in ovarian cancer
por: Ferrandina, Gabriella, et al.
Publicado: (2009)

BRCA mutations in the manifestation and treatment of ovarian cancer
por: Pan, Zimin, et al.
Publicado: (2017)

Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers
por: Zaaijer, Leendert H, et al.
Publicado: (2016)

Reflex BRCA1 and BRCA2 tumour genetic testing for high-grade serous ovarian cancer: streamlined for clinicians but what do patients think?
por: McCuaig, Jeanna M., et al.
Publicado: (2022)

BRCA-Associated Ovarian Cancer: From Molecular Genetics to Risk Management
por: Girolimetti, Giulia, et al.
Publicado: (2014)

Spectrum of Germline BRCA1 and BRCA2 Variants Identified in 2351 Ovarian and Breast Cancer Patients Referring to a Reference Cancer Hospital of Rome
por: Santonocito, Concetta, et al.
Publicado: (2020)

Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer
por: Kim, Se Ik, et al.
Publicado: (2019)

Spectrum of TP53 Mutations in BRCA1/2 Associated High-Grade Serous Ovarian Cancer
por: Boyarskikh, Ulyana A., et al.
Publicado: (2020)

Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer
por: Eoh, Kyung Jin, et al.
Publicado: (2020)

Germline and tumor BRCA1/2 mutations in Chinese high grade serous ovarian cancer patients
por: Ji, Gang, et al.
Publicado: (2021)

PARP Inhibitors Display Differential Efficacy in Models of BRCA Mutant High-Grade Serous Ovarian Cancer
por: Dickson, Kristie-Ann, et al.
Publicado: (2021)

Differential Sensitivity of Germline and Somatic BRCA Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer
por: Vendrell, Julie A., et al.
Publicado: (2023)

Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil
por: Maistro, Simone, et al.
Publicado: (2016)

Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer
por: Kalachand, Roshni D., et al.
Publicado: (2020)

BRCA1 and BRCA2 mutations in ovarian cancer patients from Belarus: update
por: Savanevich, Alena, et al.
Publicado: (2021)

Hereditary Ovarian Carcinoma: Cancer Pathogenesis Looking beyond BRCA1 and BRCA2
por: Samuel, David, et al.
Publicado: (2022)

Landscape of germline BRCA1/BRCA2 variants in breast and ovarian cancer in Peru
por: Ferreyra, Yomali, et al.
Publicado: (2023)

Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2
por: O’Mahony, Denise G., et al.
Publicado: (2023)

Cyclo-oxygenase-2 (Cox-2) expression and resistance to platinum versus platinum/paclitaxel containing chemotherapy in advanced ovarian cancer
por: Ferrandina, Gabriella, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_vjpakmnsoa6drdgfdon0i41od8